Ferric citrate hydrate is associated with a reduced cost of drugs and a smaller change in red blood cell distribution width
Abstract The ASTRIO study was a randomised, multicentre, 24-week study that compared the effects of ferric citrate hydrate (FC) and non-iron-based phosphate binders (control) on anaemia management in haemodialysis (HD) patients receiving erythropoiesis-stimulating agents (ESAs). In that study, FC re...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-02-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-06261-0 |
| _version_ | 1819279539689226240 |
|---|---|
| author | Kyoko Ito Keitaro Yokoyama Masaaki Nakayama Masafumi Fukagawa Hideki Hirakata |
| author_facet | Kyoko Ito Keitaro Yokoyama Masaaki Nakayama Masafumi Fukagawa Hideki Hirakata |
| author_sort | Kyoko Ito |
| collection | DOAJ |
| description | Abstract The ASTRIO study was a randomised, multicentre, 24-week study that compared the effects of ferric citrate hydrate (FC) and non-iron-based phosphate binders (control) on anaemia management in haemodialysis (HD) patients receiving erythropoiesis-stimulating agents (ESAs). In that study, FC reduced the doses of ESAs and intravenous iron without affecting haemoglobin (Hb); however, the cost-effectiveness of FC was unclear. We retrospectively implemented a cost-effectiveness analysis comparing the incremental cost-effectiveness ratios (ICERs) in FC (n = 42) and control (n = 40) groups in patients with serum phosphate and Hb controlled within the ranges of 3.5–6.0 mg/dL and 10–12 g/dL, respectively. Costs included drug costs of phosphate binders, ESAs, and intravenous iron. Elevated red cell distribution width (RDW) has been reported to be associated with mortality in HD patients and was therefore used as an effectiveness index. The mean (95% confidence interval) differences in drug costs and RDW between the FC and control groups were US$ − 421.36 (− 778.94 to − 63.78, p = 0.02) and − 0.83% (− 1.61 to – 0.05, p = 0.04), respectively. ICER indicated a decrease of US$ 507.66 per 1% decrease in RDW. FC was more cost-effective than non-iron-based phosphate binders. Iron absorbed via FC could promote erythropoiesis and contribute to renal anaemia treatment. |
| first_indexed | 2024-12-24T00:29:31Z |
| format | Article |
| id | doaj.art-7705fdeb260f4bdd8e47266b578929ca |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-24T00:29:31Z |
| publishDate | 2022-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-7705fdeb260f4bdd8e47266b578929ca2022-12-21T17:24:20ZengNature PortfolioScientific Reports2045-23222022-02-011211910.1038/s41598-022-06261-0Ferric citrate hydrate is associated with a reduced cost of drugs and a smaller change in red blood cell distribution widthKyoko Ito0Keitaro Yokoyama1Masaaki Nakayama2Masafumi Fukagawa3Hideki Hirakata4Medical Affairs Department, Torii Pharmaceutical Co. LtdDepartment of Health Science, The Graduate School, The Jikei University School of MedicineSt. Luke’s International Hospital, St. Luke’s International UniversityDivision of Nephrology, Endocrinology and Metabolism, Tokai University School of MedicineFukuoka Renal ClinicAbstract The ASTRIO study was a randomised, multicentre, 24-week study that compared the effects of ferric citrate hydrate (FC) and non-iron-based phosphate binders (control) on anaemia management in haemodialysis (HD) patients receiving erythropoiesis-stimulating agents (ESAs). In that study, FC reduced the doses of ESAs and intravenous iron without affecting haemoglobin (Hb); however, the cost-effectiveness of FC was unclear. We retrospectively implemented a cost-effectiveness analysis comparing the incremental cost-effectiveness ratios (ICERs) in FC (n = 42) and control (n = 40) groups in patients with serum phosphate and Hb controlled within the ranges of 3.5–6.0 mg/dL and 10–12 g/dL, respectively. Costs included drug costs of phosphate binders, ESAs, and intravenous iron. Elevated red cell distribution width (RDW) has been reported to be associated with mortality in HD patients and was therefore used as an effectiveness index. The mean (95% confidence interval) differences in drug costs and RDW between the FC and control groups were US$ − 421.36 (− 778.94 to − 63.78, p = 0.02) and − 0.83% (− 1.61 to – 0.05, p = 0.04), respectively. ICER indicated a decrease of US$ 507.66 per 1% decrease in RDW. FC was more cost-effective than non-iron-based phosphate binders. Iron absorbed via FC could promote erythropoiesis and contribute to renal anaemia treatment.https://doi.org/10.1038/s41598-022-06261-0 |
| spellingShingle | Kyoko Ito Keitaro Yokoyama Masaaki Nakayama Masafumi Fukagawa Hideki Hirakata Ferric citrate hydrate is associated with a reduced cost of drugs and a smaller change in red blood cell distribution width Scientific Reports |
| title | Ferric citrate hydrate is associated with a reduced cost of drugs and a smaller change in red blood cell distribution width |
| title_full | Ferric citrate hydrate is associated with a reduced cost of drugs and a smaller change in red blood cell distribution width |
| title_fullStr | Ferric citrate hydrate is associated with a reduced cost of drugs and a smaller change in red blood cell distribution width |
| title_full_unstemmed | Ferric citrate hydrate is associated with a reduced cost of drugs and a smaller change in red blood cell distribution width |
| title_short | Ferric citrate hydrate is associated with a reduced cost of drugs and a smaller change in red blood cell distribution width |
| title_sort | ferric citrate hydrate is associated with a reduced cost of drugs and a smaller change in red blood cell distribution width |
| url | https://doi.org/10.1038/s41598-022-06261-0 |
| work_keys_str_mv | AT kyokoito ferriccitratehydrateisassociatedwithareducedcostofdrugsandasmallerchangeinredbloodcelldistributionwidth AT keitaroyokoyama ferriccitratehydrateisassociatedwithareducedcostofdrugsandasmallerchangeinredbloodcelldistributionwidth AT masaakinakayama ferriccitratehydrateisassociatedwithareducedcostofdrugsandasmallerchangeinredbloodcelldistributionwidth AT masafumifukagawa ferriccitratehydrateisassociatedwithareducedcostofdrugsandasmallerchangeinredbloodcelldistributionwidth AT hidekihirakata ferriccitratehydrateisassociatedwithareducedcostofdrugsandasmallerchangeinredbloodcelldistributionwidth |